BioSpace News Archive

OncoSec Medical Incorporated (NASDAQ: ONCS) (the “Company” or “OncoSec”), a company developing late-stage intratumoral cancer immunotherapies, today announced that Institutional Shareholder Services Inc. (“ISS”), a leading proxy advisory firm that provides objective and independent analysis and voting recommendations for contested situations

The inaugural Gainbridge LPGA at Boca Rio is pleased to announce the event week will feature the Women’s Leadership Summit presented by Versant Health on January 21, 2020.

Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) to update the product label for ZILRETTA (triamcinolone acetonide extended-release injectable suspension) for the treatment of osteoarthritis (OA) knee pain.

Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced the completion of patient enrollment in its Sulopenem for Resistant Enterobacteriaceae (SURE) 1 clinical trial in uncomplicated urinary tract infections (uUTI).

Luye Pharma Group has announced submission of a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for LY03005, a new chemical drug for the treatment of major depressive disorder.

Sensyne Health plc (LSE: SENS), the British clinical AI technology company, today announced it has signed a research project with Roche. Initially the collaboration will focus on identifying patient populations in one disease area and assessing and collating anonymised patient data with anonymised electronic patient record (EHR) information to support clinical trial planning

Expedeon AG (Frankfurt: EXNN; ISIN: DE000A2YN801; Prime Standard) today announced that the Company’s Extraordinary General Meeting (EGM) held in Heidelberg today has approved all management proposals by a large majority without objection.

Spring Bank Pharmaceuticals, Inc. announced that the company has stopped dosing and enrolling patients in its Phase 2b CATALYST trials, which are examining the use of inarigivir soproxil 400mg for the treatment of chronic hepatitis B virus.

Microbot Medical Inc. announced that it has entered into definitive agreements with certain institutional investors for the purchase in a registered direct offering of 912,858 shares of its common stock, at a purchase price per share of $10.50, priced at-the-market under Nasdaq rules.

HEXO Corp. (“HEXO” or the “Company”) (TSX: HEXO; NYSE: HEXO) today announced it has entered into a definitive agreement with institutional investors for the purchase and sale of 14,970,062 common shares at an offering price of US$1.67 per share for gross proceeds of US$25.0 million before deducting fees and other estimated offering expenses, pursuant to a registered direct offering (the “Offering”).